

Novavax COVID-19 Vaccine (Adjuvanted) Authorized and Available for Use

BACKGROUND

On 10/3/2023, the FDA amended the emergency use authorization (EUA) of **Novavax COVID-19 Vaccine**, **Adjuvanted** (hereafter referred to as Novavax COVID-19 Vaccine) to the 2023-2024 formula, revised to include spike protein from the SARS-CoV-2 Omicron variant lineage XBB.1.5. The original Novavax COVID-19 Vaccine is no longer authorized for use.

The authorization and availability of this updated **protein subunit vaccine** brings the total array of currently licensed or authorized adult COVID-19 vaccines to three (3): Spikevax[®], Comirnaty[®], and Novavax COVID-19 Vaccine.

PharMerica previously shared a <u>Clinical Advisory</u> and <u>Did You Know</u> on the two former 2023-24 COVID-19 vaccines: **Spikevax** (Moderna) and **Comirnaty** (Pfizer), which are similarly **monovalent** and **updated to the 2023-24 formula**, but which in contrast are **fully licensed** and **mRNA-based**.

Novavax COVID-19 Vaccine is emergency use authorized in individuals ≥12 years of age as follows:

- Individuals previously vaccinated with any COVID-19 vaccine: 1 dose of Novavax COVID-19 Vaccine is administered ≥2 months after receipt of the last previous dose of an original monovalent or bivalent COVID-19 vaccine.
- Individuals not previously vaccinated with any COVID-19 vaccine: 2 doses of Novavax COVID-19 Vaccine are administered 3 weeks apart.
- Immunocompromised individuals: an additional dose of Novavax COVID-19 Vaccine may be administered ≥2 months following the last dose of a COVID-19 vaccine (2023-2024 Formula). Additional doses of Novavax COVID-19 Vaccine may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances. The timing of the additional doses may be based on the individual's clinical circumstances.

ORDERING INFORMATION

• Place resident orders as you would for other Part B vaccines (e.g., influenza or pneumococcal vaccines).

Skilled Nursing Facility 2023-2024 COVID-19 Vaccine Pricing						
Product	PharMerica Per Dose Cost		CMS National Payment Allowance			
MODERNA - SPIKEVAX 2023-24(12Y+) SYRINGE	\$	125.00	\$ 145.92			
MODERNA - SPIKEVAX 2023-24(12Y+) SDV	\$	125.00	\$ 145.92			
NOVAVAX - COVID-19 VACCINE(12Y+) MDV (5 doses)	\$	125.00	\$ 148.20			
PFIZER - COMIRNATY 2023-24(12Y+) SDV	\$	125.00	\$ 131.10			

DOCUMENTATION/BILLING INFORMATION

• For adults with Medicare, COVID-19 Vaccines are reimbursed under Medicare Part B, even if in Part A stay.

CPT/HCPCS Code	Labeler Name	Vaccine Name	National Payment Allowance	Effective Dates
90480	-	COVID-19 Vaccine Administration	\$40.00	9/11/23 – TBD
91320	Pfizer-BioNTech	COMIRNATY (2023-24 Formula)	\$131.10	9/11/23 – TBD
91322	Moderna	SPIKEVAX (2023-24 Formula)	\$145.92	9/11/23 – TBD
91304	Novavax	Novavax COVID-19 Vaccine	\$148.20	07/13/22 – TBD

©Copyright PharMerica 2023. All rights reserved. Material presented in this document is for general informational purposes only and all treatment decisions should ultimately be made using professional judgment by qualified health care professionals directly involved in the patient's care.



ADDITIONAL RESOURCES Recommended updated (2023–2024 Formula) COVID-19 vaccines for CDC's Interim Clinical people who are **NOT** moderately or severely immunocompromised** Considerations for Use of COVID-19 Vaccines in the United States Unvaccinated Vaccinated COVID-19 vaccine CDC's Recommended dose(s) received updated (2023–2024 before availability 3 or more **C** 1 dose 2 doses Formula) COVID-19 2 or more YEA of updated (2023-1 dose any doses any any Pfizer doses any any Pfizer vaccines for people who 2024 Formula) Moderna Pfizer Moderna BioNTech BioNTech BioNTech COVID-19 vaccines are NOT moderately or 4 severely immunocompromised MONTH Ы ν 3 doses 1 dose 2 doses 1 dose Recommendations CDC's Recommended for updated updated (2023-2024 2023-2024 2024 202 2023-202 (2023-2024 ¢ Formula) COVID-19 Pfizer Mode Formula) vaccine. BioNTech RigNTech oNTech vaccines for by manufacturer 0.25 mL/25 μg 0.3 mL/3 uo 0.25 mL/25 µg 0.3 mL/3 µg 0.3 mL/3 μg people who ARE moderately or severely immunocompromised Unvaccinated Vaccinated FDA Fact Sheets for Health Care Providers and COVID-19 vaccine Patients dose(s) received before availability 1 or more of updated (2023doses any 2024 Formula) **VEARS** mRNA vaccine COVID-19 vaccines 1 dose 1 dose Recommendations for updated (2023-2024 2023-2024 Made Formula) vaccine, by manufacturer 0.25 mL/25 μg 0.3 mL/10 µg Unvaccinated Vaccinated COVID-19 vaccine dose(s) received œ before availability 1 or more doses Novavax or OLDE 1 or more Janssen, including in combination with any Original monovalent or of updated (2023doses any 2024 Formula) mRNA vaccine bivalent COVID-19 vaccine doses **COVID-19 vaccines** AND YEARS 1 dose 1 dose 1 dose doses 1 dose 1 dos Recommendations for updated (2023-2024 2023-2024 2023-2024 Moderna 2023–2024 Moderna 23-202 023-202 Formula) vaccine, Novava by manufacturer 0.5 mL/5 µg 50 µg adiuvan/ 0.5 mL/5 μg 0.5 mL/50 µg 0.5 mL/50 µp 0.3 mL/30 µg 0.3 mL/30 µ *For information about administration intervals and children who transition from age 4 years to age 5 years, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines, 'COVID-19 vaccination history refers to previous receipt of doses of Original monovalent mRNA or bivalent mRNA vaccine or a combination of the two; for people ages 12 years and older, Original monovalent Novavax COVID-19 Vaccine doses, alone or in combination with any mRNA vaccine doses; and for people ages 18 years and older, Janssen COVID-19 Vaccine doses, alone or in combination with any mRNA or Original monovalent Novavax vaccine doses

Novavax COVID-19 Vaccine (Adjuvanted) Authorized and Available for Use

©Copyright PharMerica 2023. All rights reserved. Material presented in this document is for general informational purposes only and all treatment decisions should ultimately be made using professional judgment by qualified health care professionals directly involved in the patient's care.

Centers for Disease Control and Prevention

10/13/23